{"id":2875,"date":"2018-04-10T11:55:27","date_gmt":"2018-04-10T17:55:27","guid":{"rendered":"https:\/\/www.epicore.ualberta.ca\/home\/\/?p=2875"},"modified":"2020-05-27T11:13:38","modified_gmt":"2020-05-27T17:13:38","slug":"scripplus","status":"publish","type":"post","link":"https:\/\/www.epicore.ualberta.ca\/home\/scripplus\/","title":{"rendered":"An Evaluation of the Impact of a Comprehensive Community Pharmacist Intervention Program on the Management of Patients at High-risk for Coronary Heart Disease"},"content":{"rendered":"<p><strong>Primary Study Objective:<\/strong><br \/>\nTo determine the effect of a community-pharmacist intervention program on LDL-C in patients at high-risk for cardiovascular disease.<\/p>\n<p><strong>Secondary Study Objectives:<\/strong><br \/>\n(1) efficacy of a web-based educational module<br \/>\n(2) patient satisfaction with pharmacist services<br \/>\n(3) patient compliance with lipid-lowering medications<br \/>\n(4) proportion of patients achieving target LDL-C and TC:HDL ratio<br \/>\n(5) cost analysis of providing the clinic.<\/p>\n<p><strong>Primary Endpoint:<\/strong><br \/>\nChange in the LDL-C from baseline to study end (6 months)<\/p>\n<p><strong>Primary Investigators:<\/strong><br \/>\nTsuyuki RT, Olson KL<\/p>\n<p><strong>Co-Investigators:<\/strong><br \/>\nSchindel T, Johnson J, Taylor J.<\/p>\n<p><strong>Time Line:<\/strong><br \/>\nEnrollment commenced October 2000; Follow-up completed January 2002<\/p>\n<p><strong>Publications: <\/strong><br \/>\nTsuyuki, R. T., et al. (2004). Effect of Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk of Cardiovascular Events: The Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). The American Journal of Medicine, 116, 130-133. (<a href=\"https:\/\/www.epicore.ualberta.ca\/Documents\/Tsuyuki%20SCRIPplus%20AJMed2004.pdf\" rel=\"noopener\" target=\"_blank\">link<\/a>)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Primary Study Objective: To determine the effect of a community-pharmacist intervention program on LDL-C in patients at high-risk for cardiovascular disease. Secondary Study Objectives: (1) efficacy of a web-based educational module (2) patient satisfaction with pharmacist services (3) patient compliance with lipid-lowering medications (4) proportion of patients achieving target LDL-C and TC:HDL ratio (5) cost [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[31],"tags":[],"_links":{"self":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts\/2875"}],"collection":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/comments?post=2875"}],"version-history":[{"count":6,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts\/2875\/revisions"}],"predecessor-version":[{"id":2901,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/posts\/2875\/revisions\/2901"}],"wp:attachment":[{"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/media?parent=2875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/categories?post=2875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.epicore.ualberta.ca\/home\/wp-json\/wp\/v2\/tags?post=2875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}